ORIC

ORIC Pharmaceuticals, Inc.

Price Chart

Latest Quote

$8.93

+0.44 (+5.18%)

Current Price

Previous Close	$8.49
Open	$8.67
Day High	$9.13
Day Low	$8.67
Volume	1,775,608

Fetched: 2026-06-23T09:35:05

Stock Information

Shares Outstanding	103.52M
Total Debt	$6.73M
Cash Equivalents	$281.93M
Net Income	$-135.21M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$924.41M
EPS (TTM)	$-1.39
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$649.21M
Income	$-135.21M
Book/sh	$4.02
Cash/sh	$2.72
Employees	104

Financial Ratios

Quick Ratio	15.87
Current Ratio	16.33
Debt/Eq	1.62

Returns & Margins

ROA	-27.57%
ROE	-42.57%

Ownership

Insider Ownership	5.85%
Institutional Ownership	114.17%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-5.67
P/B	2.22

Analyst Data

Recommendation	strong_buy
Target Price	$20.29

Technical Indicators

SMA20	$8.21
SMA50	$9.01
SMA200	$10.69
RSI	49.51
ATR	0.6226

Shares Float	82.53M
Short Float	21.42%
Short Ratio	16.13
Volatility	1.06
Rel Volume	0.94

Performance History

Week	+7.98%
Month	+6.18%
Quarter	-19.98%
6 Months	+8.64%
YTD	+9.30%
Year	-3.15%
3 Years	+41.07%
5 Years	-54.69%
10 Years	-65.35%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-22	$8.93	1,775,700
2026-06-18	$8.49	2,771,200
2026-06-17	$8.63	1,434,500
2026-06-16	$8.31	1,151,000
2026-06-15	$8.40	1,225,500
2026-06-12	$8.27	1,561,400
2026-06-11	$7.82	2,190,400
2026-06-10	$7.54	2,085,200
2026-06-09	$8.00	1,714,700
2026-06-08	$7.53	1,762,000
2026-06-05	$7.50	1,246,100
2026-06-04	$8.02	1,068,200
2026-06-03	$7.84	2,284,000
2026-06-02	$7.62	4,020,600
2026-06-01	$8.98	3,679,900
2026-05-29	$8.45	3,971,100
2026-05-28	$8.45	1,514,400
2026-05-27	$8.58	766,700
2026-05-26	$8.54	913,800

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

📰 Latest News

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

Simply Wall St. • 2026-05-17T13:23:04Z

A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data

Simply Wall St. • 2026-04-06T09:08:12Z

Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM

BioPharma Dive • 2026-04-02T12:20:00Z

ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3

Simply Wall St. • 2026-04-02T08:13:22Z

Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges

Investor's Business Daily • 2026-04-01T20:16:00Z

Oric Shares Fall 40% as Cancer-Drug Data Falls Short of Expectations

The Wall Street Journal • 2026-04-01T20:05:29Z

Wall Street Set to Open Higher as Trump Says US Will Consider Ceasefire if Hormuz Strait Opened

MT Newswires • 2026-04-01T13:16:37Z

Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial

MarketBeat • 2026-03-31T23:07:08Z

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.

Motley Fool • 2026-03-19T19:23:04Z

Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns

Simply Wall St. • 2026-03-13T09:11:29Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$143,004,000	$142,895,000	$110,780,000	$86,767,000
Other Income Expense	$13,536,000	$15,048,000	$10,083,000	$-2,355,000
Other Non Operating Income Expenses	$13,536,000	$15,048,000	$10,083,000	$2,645,000
Operating Expense	$143,004,000	$142,895,000	$110,780,000	$86,767,000
General And Administrative Expense	$33,186,000	$28,823,000	$25,608,000	$25,087,000
Net Non Operating Interest Income Expense	-	-	-	$2,645,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-129,468,000	$-127,847,000	$-100,697,000	$-89,122,000
Normalized Income	$-129,468,000	$-127,847,000	$-100,697,000	$-84,122,000
Net Income From Continuing And Discontinued Operation	$-129,468,000	$-127,847,000	$-100,697,000	$-89,122,000
Total Operating Income As Reported	$-143,004,000	$-142,895,000	$-110,780,000	$-91,767,000
Net Income Common Stockholders	$-129,468,000	$-127,847,000	$-100,697,000	$-89,122,000
Net Income	$-129,468,000	$-127,847,000	$-100,697,000	$-89,122,000
Net Income Including Noncontrolling Interests	$-129,468,000	$-127,847,000	$-100,697,000	$-89,122,000
Net Income Continuous Operations	$-129,468,000	$-127,847,000	$-100,697,000	$-89,122,000
Pretax Income	$-129,468,000	$-127,847,000	$-100,697,000	$-89,122,000
Operating Income	$-143,004,000	$-142,895,000	$-110,780,000	$-86,767,000
Special Income Charges	-	-	$0	$-5,000,000
Net Interest Income	-	-	-	$2,645,000
Interest Income	-	-	-	$2,645,000
Interest Income Non Operating	-	-	-	$2,645,000
Per Share
Diluted EPS	$-1.47	$-1.83	$-1.96	$-2.25
Basic EPS	$-1.47	$-1.83	$-1.96	$-2.25
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-141,784,000	$-141,788,000	$-109,748,000	$-80,801,000
Reconciled Depreciation	$1,220,000	$1,107,000	$1,032,000	$966,000
EBITDA (Bullshit earnings)	$-141,784,000	$-141,788,000	$-109,748,000	$-85,801,000
EBIT	$-143,004,000	$-142,895,000	$-110,780,000	$-86,767,000
Diluted Average Shares	$87,793,801	$69,727,940	$51,450,848	$39,655,260
Basic Average Shares	$87,793,801	$69,727,940	$51,450,848	$39,655,260
Diluted NI Availto Com Stockholders	$-129,468,000	$-127,847,000	$-100,697,000	$-89,122,000
Research And Development	$109,818,000	$114,072,000	$85,172,000	$61,680,000
Selling General And Administration	$33,186,000	$28,823,000	$25,608,000	$25,087,000
Other Gand A	$33,186,000	$28,823,000	$25,608,000	$25,087,000
Total Unusual Items	-	-	$0	$-5,000,000
Total Unusual Items Excluding Goodwill	-	-	$0	$-5,000,000
Other Special Charges	-	-	-	$5,000,000

Fetched: 2026-06-20

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$384,362,000	$243,122,000	$224,088,000	$222,351,000
Total Assets	$408,890,000	$274,142,000	$252,007,000	$247,178,000
Total Non Current Assets	$120,424,000	$11,892,000	$39,410,000	$36,721,000
Other Non Current Assets	$7,247,000	$8,968,000	$9,696,000	$11,517,000
Investmentin Financial Assets	$110,762,000	$0	$26,852,000	$21,951,000
Current Assets	$288,466,000	$262,250,000	$212,597,000	$210,457,000
Other Current Assets	$6,978,000	$6,290,000	$4,410,000	$4,185,000
Cash Cash Equivalents And Short Term Investments	$281,488,000	$255,960,000	$208,187,000	$206,272,000
Cash And Cash Equivalents	$45,669,000	$59,406,000	$23,384,000	$66,840,000
Prepaid Assets	-	-	-	-
Debt
Total Debt	$3,330,000	$3,183,000	$2,752,000	$2,659,000
Current Debt And Capital Lease Obligation	$3,330,000	$3,183,000	$2,752,000	$2,659,000
Liabilities
Total Liabilities Net Minority Interest	$24,528,000	$31,020,000	$27,919,000	$24,827,000
Total Non Current Liabilities Net Minority Interest	$4,111,000	$6,174,000	$7,461,000	$9,439,000
Other Non Current Liabilities	$4,111,000	$6,174,000	$7,461,000	$9,439,000
Current Liabilities	$20,417,000	$24,846,000	$20,458,000	$15,388,000
Payables And Accrued Expenses	$8,993,000	$14,015,000	$11,177,000	$7,411,000
Payables	$3,824,000	$1,548,000	$944,000	$1,320,000
Accounts Payable	$3,824,000	$1,548,000	$944,000	$1,320,000
Current Deferred Liabilities	-	-	-	-
Equity
Common Stock Equity	$384,362,000	$243,122,000	$224,088,000	$222,351,000
Total Equity Gross Minority Interest	$384,362,000	$243,122,000	$224,088,000	$222,351,000
Stockholders Equity	$384,362,000	$243,122,000	$224,088,000	$222,351,000
Gains Losses Not Affecting Retained Earnings	$786,000	$379,000	$258,000	$-1,291,000
Other Equity Adjustments	$786,000	$379,000	$258,000	$-1,291,000
Retained Earnings	$-692,242,000	$-562,774,000	$-434,927,000	$-334,230,000
Other
Ordinary Shares Number	$98,528,949	$71,021,855	$54,865,553	$45,089,537
Share Issued	$98,528,949	$71,021,855	$54,865,553	$45,089,537
Tangible Book Value	$384,362,000	$243,122,000	$224,088,000	$222,351,000
Invested Capital	$384,362,000	$243,122,000	$224,088,000	$222,351,000
Working Capital	$268,049,000	$237,404,000	$192,139,000	$195,069,000
Capital Lease Obligations	$3,330,000	$3,183,000	$2,752,000	$2,659,000
Total Capitalization	$384,362,000	$243,122,000	$224,088,000	$222,351,000
Additional Paid In Capital	$1,075,807,000	$805,510,000	$658,751,000	$557,867,000
Capital Stock	$11,000	$7,000	$6,000	$5,000
Common Stock	$11,000	$7,000	$6,000	$5,000
Preferred Stock	$0	$0	$0	$0
Current Capital Lease Obligation	$3,330,000	$3,183,000	$2,752,000	$2,659,000
Pensionand Other Post Retirement Benefit Plans Current	$8,094,000	$7,648,000	$6,529,000	$5,318,000
Current Accrued Expenses	$5,169,000	$12,467,000	$10,233,000	$6,091,000
Investments And Advances	$110,762,000	$0	$26,852,000	$21,951,000
Available For Sale Securities	$110,762,000	-	$26,852,000	$21,951,000
Net PPE	$2,415,000	$2,924,000	$2,862,000	$3,253,000
Accumulated Depreciation	$-7,651,000	$-7,476,000	$-6,494,000	$-5,793,000
Gross PPE	$10,066,000	$10,400,000	$9,356,000	$9,046,000
Leases	$2,065,000	$2,043,000	$1,967,000	$1,978,000
Other Properties	$7,012,000	$7,386,000	$6,596,000	$6,249,000
Machinery Furniture Equipment	$989,000	$971,000	$793,000	$819,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$235,819,000	$196,554,000	$184,803,000	$139,432,000

Fetched: 2026-06-20

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-111,682,000	$-113,850,000	$-86,537,000	$-77,221,000
Operating Activities
Operating Cash Flow	$-110,970,000	$-112,662,000	$-85,688,000	$-75,143,000
Cash Flow From Continuing Operating Activities	$-110,970,000	$-112,662,000	$-85,688,000	$-75,143,000
Operating Gains Losses	-	-	$22,000	$40,000
Investing Activities
Capital Expenditure	$-712,000	$-1,188,000	$-849,000	$-2,078,000
Investing Cash Flow	$-148,031,000	$22,137,000	$-43,403,000	$-109,248,000
Cash Flow From Continuing Investing Activities	$-148,031,000	$22,137,000	$-43,403,000	$-109,248,000
Financing Activities
Issuance Of Capital Stock	$244,369,000	$125,000,000	$85,000,000	$25,000,000
Financing Cash Flow	$245,264,000	$126,547,000	$85,658,000	$25,225,000
Cash Flow From Continuing Financing Activities	$245,264,000	$126,547,000	$85,658,000	$25,225,000
Net Other Financing Charges	$-2,397,000	$-168,000	$-227,000	$-399,000
Net Common Stock Issuance	$244,369,000	$125,000,000	$85,000,000	$25,000,000
Common Stock Issuance	$244,369,000	$125,000,000	$85,000,000	$25,000,000
Net Preferred Stock Issuance	-	-	-	-
Preferred Stock Issuance	-	-	-	-
Other
End Cash Position	$46,160,000	$59,897,000	$23,875,000	$67,308,000
Beginning Cash Position	$59,897,000	$23,875,000	$67,308,000	$226,474,000
Changes In Cash	$-13,737,000	$36,022,000	$-43,433,000	$-159,166,000
Proceeds From Stock Option Exercised	$3,292,000	$1,715,000	$885,000	$624,000
Net Investment Purchase And Sale	$-147,319,000	$23,325,000	$-42,554,000	$-107,170,000
Sale Of Investment	$252,500,000	$275,245,000	$196,690,000	$130,954,000
Purchase Of Investment	$-399,819,000	$-251,920,000	$-239,244,000	$-238,124,000
Net PPE Purchase And Sale	$-712,000	$-1,188,000	$-849,000	$-2,078,000
Purchase Of PPE	$-712,000	$-1,188,000	$-849,000	$-2,078,000
Change In Working Capital	$-5,459,000	$1,968,000	$4,898,000	$-445,000
Change In Payables And Accrued Expense	$-7,246,000	$1,825,000	$3,278,000	$-1,475,000
Change In Prepaid Assets	$1,787,000	$143,000	$1,620,000	$1,030,000
Stock Based Compensation	$25,037,000	$20,213,000	$15,226,000	$14,460,000
Amortization Of Securities	$-2,300,000	$-8,103,000	$-6,169,000	$-1,042,000
Depreciation Amortization Depletion	$1,220,000	$1,107,000	$1,032,000	$966,000
Depreciation And Amortization	$1,220,000	$1,107,000	$1,032,000	$966,000
Depreciation	$1,220,000	$1,107,000	$1,032,000	$966,000
Net Income From Continuing Operations	$-129,468,000	$-127,847,000	$-100,697,000	$-89,122,000
Gain Loss On Sale Of PPE	-	$0	$22,000	$40,000
Change In Payable	-	-	-	-
Change In Account Payable	-	-	-	-

Fetched: 2026-06-20